VItamin K In PEritonial DIAlysis (VIKIPEDIA): Rationale and study protocol for a randomized controlled trial
Open Access
- 17 August 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (8) , e0273102
Abstract
Vascular calcification (VC) is an active process, resulting from the disturbance of balance between inhibitors and promoters of calcification, in favor of the latter. Matrix Gla Protein, a powerful inhibitor of VC, needs vitamin K to become active. In vitamin K depletion, plasma levels of the inactive form of MGP, dephosphorylated, uncarboxylated MGP (dp-ucMGP) are increased and associated with VC and cardiovascular (CV) outcomes. End Stage Renal Disease (ESRD) patients have increased circulating dp-ucMGP levels and accelerated VC. VItamin K In PEritoneal DIAlysis (VIKIPEDIA) is a prospective, randomized, open label, placebo-controlled trial, evaluating the effect of vitamin K2 supplementation on arterial stiffness and CV events in ESRD patients undergoing peritoneal dialysis (PD). Forty-four PD patients will be included in the study. At baseline, dp-ucMGP and pulse-wave velocity (PWV) will be assessed and then patients will be randomized (1:1 ratio) to vitamin K (1000 μg MK-7/day) or placebo for 1.5 years. The primary endpoint of this trial is the change in PWV in the placebo group as compared to the treatment group. Secondary endpoints are the occurrence of CV events, mortality, changes in PD adequacy, change in 24-hour ambulatory blood pressure indexes and aortic systolic blood pressure and changes in calcium/phosphorus/parathormone metabolism. VIKIPEDIA is a new superiority randomized, open label, placebo-controlled trial aiming to determine the effect of vitamin K2 supplementation on VC, CV disease and calcium/phosphorus metabolism, in PD patients. Trial registration: The protocol of this study is registered at ClinicalTrials.gov with identification number NCT04900610 (25 May 2021).Keywords
This publication has 39 references indexed in Scilit:
- The Circulating Inactive Form of Matrix Gla Protein Is a Surrogate Marker for Vascular Calcification in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2010
- Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) speciesThrombosis and Haemostasis, 2010
- ForewordKidney International, 2009
- Vascular StiffnessClinical Journal of the American Society of Nephrology, 2008
- Matrix Gla Protein Is Associated With Risk Factors for Atherosclerosis but not With Coronary Artery CalcificationArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Aortic pulse wave velocity index and mortality in end-stage renal diseaseKidney International, 2003
- Prognostic significance of arterial stiffness measurements in end-stage renal disease patientsCurrent Opinion in Nephrology and Hypertension, 2002
- Determination of Phylloquinone and Menaquinones in FoodPathophysiology of Haemostasis and Thrombosis, 2000
- Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA proteinNature, 1997
- Production of a New Monoclonal Antibody Specific to Human Des-Gamma-Carboxyprothrombin in the Presence of Calcium Ions. Application to the Development of a Sensitive ELISA-TestJournal of Immunoassay, 1995